Oxford Biomedica Plc (OXB) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

PureTech Health Plc

Optibiotix Health Plc

Diaceutics Plc

Ondine Biomedical, Inc.

4basebio Plc

Oxford Biomedica Plc

Scancell Holdings Plc

Oxford BioDynamics Plc

HemoGenyx Pharmaceuticals Plc

e-Therapeutics Plc

Oncimmune Holdings Plc

Why is Oxford Biomedica Plc ?

Poor Management Efficiency with a low ROE of 2.05%

The company has been able to generate a Return on Equity (avg) of 2.05% signifying low profitability per unit of shareholders funds

Poor long term growth as Operating profit has grown by an annual rate -186.74% of over the last 5 years

Flat results in Jun 25

OPERATING CASH FLOW(Y) Lowest at GBP -68.39 MM
DEBT-EQUITY RATIO (HY) Highest at 157.5 %
RAW MATERIAL COST(Y) Grown by 15.46% (YoY)

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 101.96%, its profits have risen by 43.1%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Oxford Biomedica Plc for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Oxford Biomedica Plc

101.63%

-0.25

48.91%

FTSE 100

13.98%

1.15

13.60%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

18.06%

EBIT Growth (5y)

-186.74%

EBIT to Interest (avg)

-0.59

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.29

Sales to Capital Employed (avg)

0.90

Tax Ratio

2.84%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.07%

ROE (avg)

2.05%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

23.54

EV to EBIT

-22.54

EV to EBITDA

-82.76

EV to Capital Employed

37.36

EV to Sales

5.01

PEG Ratio

Dividend Yield

ROCE (Latest)

-165.76%

ROE (Latest)

-119.43%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at GBP -26.36 MM

NET SALES(Q)

At GBP 73.22 MM has Grown at 44.12%

-10What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at GBP -68.39 MM

DEBT-EQUITY RATIO (HY)

Highest at 157.5 %

RAW MATERIAL COST(Y)

Grown by 15.46% (YoY

CASH AND EQV(HY)

Lowest at GBP 53.88 MM

INTEREST(Q)

Highest at GBP 6.76 MM

Here's what is working for Oxford Biomedica Plc

Net Profit

Higher at GBP -26.36 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (GBP MM)

Net Sales

At GBP 73.22 MM has Grown at 44.12%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (GBP MM)

Here's what is not working for Oxford Biomedica Plc

Operating Cash Flow

Lowest at GBP -68.39 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (GBP MM)

Debt-Equity Ratio

Highest at 157.5 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Interest

Highest at GBP 6.76 MM

in the last five periods and Increased by 28.52% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (GBP MM)

Cash and Eqv

Lowest at GBP 53.88 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 15.46% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales